AR032036A1 - Tratamiento de tumores inoperables por medio de inyeccion estereotactica de microesferas - Google Patents

Tratamiento de tumores inoperables por medio de inyeccion estereotactica de microesferas

Info

Publication number
AR032036A1
AR032036A1 ARP010106009A ARP010106009A AR032036A1 AR 032036 A1 AR032036 A1 AR 032036A1 AR P010106009 A ARP010106009 A AR P010106009A AR P010106009 A ARP010106009 A AR P010106009A AR 032036 A1 AR032036 A1 AR 032036A1
Authority
AR
Argentina
Prior art keywords
treatment
microspheres
stereotactic injection
inoperable tumors
tumor
Prior art date
Application number
ARP010106009A
Other languages
English (en)
Original Assignee
Ethypharm Lab Prod Ethiques
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ethypharm Lab Prod Ethiques filed Critical Ethypharm Lab Prod Ethiques
Publication of AR032036A1 publication Critical patent/AR032036A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epoxy Compounds (AREA)

Abstract

Uso de microesferas biodegradables que liberan un agente anticancerígeno, para la fabricacion de un medicamento para el uso en el tratamiento de tumores inoperables en seres humanos, en donde las microesferas biodegradables se administran por medio de inyeccion estereotáctica al tumor, al área peritumoral, o al mismo tiempo al tumor y al área peritumoral.
ARP010106009A 2000-12-22 2001-12-21 Tratamiento de tumores inoperables por medio de inyeccion estereotactica de microesferas AR032036A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25716700P 2000-12-22 2000-12-22

Publications (1)

Publication Number Publication Date
AR032036A1 true AR032036A1 (es) 2003-10-22

Family

ID=22975167

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010106009A AR032036A1 (es) 2000-12-22 2001-12-21 Tratamiento de tumores inoperables por medio de inyeccion estereotactica de microesferas

Country Status (7)

Country Link
US (2) US20020081339A1 (es)
EP (1) EP1343477A2 (es)
JP (1) JP2004529865A (es)
AR (1) AR032036A1 (es)
AU (1) AU2002234798A1 (es)
CA (1) CA2432518A1 (es)
WO (1) WO2002051388A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020081339A1 (en) * 2000-12-22 2002-06-27 Philippe Menei Treatment of inoperable tumors by stereotactic injection of microspheres
WO2005018600A2 (en) * 2003-08-22 2005-03-03 Cube Medical A/S Method of treating a patient suffering from a solid tumour
EP1732594A4 (en) * 2004-03-18 2007-10-17 St Lukes Hospital METHOD FOR THE ADMINISTRATION OF AGENTS WITH DELAYED RELEASE
EP1985286A1 (en) * 2007-04-24 2008-10-29 Biocompatibles UK Limited Microspheres for treatment of brain tumours
JP6758325B2 (ja) 2015-06-04 2020-09-23 クリティテック・インコーポレイテッド タキサン粒子およびその使用
CN114767860A (zh) 2016-04-04 2022-07-22 克里蒂泰克公司 实体肿瘤治疗方法
CA3063420A1 (en) 2017-06-09 2018-12-13 Crititech, Inc. Treatment of epithelial cysts by intracystic injection of antineoplastic particles
AU2018284247B2 (en) 2017-06-14 2020-04-30 Crititech Inc. Methods for treating lung disorders
CA3076919A1 (en) 2017-10-03 2019-04-11 Crititech, Inc. Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer
US12275986B2 (en) 2020-01-06 2025-04-15 Duke University Biomarkers associated with checkpoint immune therapy and methods of using same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6537585B1 (en) * 1999-03-26 2003-03-25 Guilford Pharmaceuticals, Inc. Methods and compositions for treating solid tumors
FR2793684B1 (fr) * 1999-05-17 2001-08-10 Ethypharm Lab Prod Ethiques Utilisation de microspheres biodegradables liberant un agent anticancereux pour le traitement du glioblastome, procede de preparation de ces microspheres et suspension les contenant
EP1246617B1 (en) * 1999-12-06 2006-09-13 Rhode Island Hospital Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of ovarian cancer
US20020081339A1 (en) * 2000-12-22 2002-06-27 Philippe Menei Treatment of inoperable tumors by stereotactic injection of microspheres

Also Published As

Publication number Publication date
EP1343477A2 (en) 2003-09-17
US20020081339A1 (en) 2002-06-27
WO2002051388A3 (en) 2003-02-13
JP2004529865A (ja) 2004-09-30
CA2432518A1 (en) 2002-07-04
US20040180095A1 (en) 2004-09-16
AU2002234798A1 (en) 2002-07-08
WO2002051388A2 (en) 2002-07-04

Similar Documents

Publication Publication Date Title
ES2249888T3 (es) Conjugados de paclitaxel solubles en agua, combinados con irradiacion para el tratamiento del cancer.
PT1053746E (pt) Utilizacao de micro-esferas biodegradaveis libertando um agente anticanceroso para o tratamento do glioblastoma
AR045179A1 (es) Uso de una combinacion de un inhibidor de la quinasa del receptor del factor de crecimiento epidermico y de agentes citotoxicos para el tratamiento e inhibicion del cancer
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
BR0102040A (pt) Uso de paclitaxel estabilizado com albumina para preparação de uma droga para o tratamento de tumores sólidos e a droga desse modo obtida
BRPI0207961B8 (pt) uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
NO20014662L (no) Fremgangsmåter og preparater for behandling av faste tumorer
BR0112311A (pt) Compostos e composições para liberar agentes ativos, forma de dosagem unitária, método para preparar ditas composições e seu uso
ES2557988T3 (es) Método para tratar enfermedades de próstata basado en el suministro local de principios activos
PA8498701A1 (es) Pirimidina-2,4,6-trionas inhibidores de metaloproteinasas
AR026610A1 (es) Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central
BR0112054A (pt) Composição formadora de micelas, e métodos para a administração e a proteção de um agente terapêutico
AR028296A1 (es) Metodos sinergisticos y composiciones para el tratamiento del cancer
GT200100037A (es) Las 5-alquilpirido (2,3-d) pirimidinas son inhibidoras de las cinasas de tirosina y que depende de la ciclina.
CL2003002277A1 (es) Composicion farmaceutica inyectable, de deposito de liberacion prolongada, que comprende un agente beneficioso disuelto o disperso en un gel constituido por un polimero bioerosionable y biocompatible; y un solvente.
AR068185A1 (es) Composiciones de tabletas de desintegracion oral de lamotrigina
BR9715022A (pt) Método para tratar de doenças prostáticas usando formulações de vitamina d por liberação sistemática e/ou prolongada
DE60126923D1 (de) Therapeutische zusammensetzungen bestehend aus antihypotensiva und antiangiogenika
AR058359A1 (es) Combinaciones
BR0210056A (pt) composições e métodos para tratamento de hiperplasia
BR0107628A (pt) l,2-diarilbenzimidazóis para tratamento de doenças que estão associadas a uma ativação microglial
BRPI0406858A (pt) Liberação controlada de agentes altamente solúveis
HRPK20030734B3 (en) A combination comprising combretastatin and anticancer agents
DE60143363D1 (de) Pharmazeutische zusammensetzungen, die die immunogenität von schwach immunogenen antigenen fördern
ATE454136T1 (de) Therapeutische zusammensetzungen zur pulmonalen verabreichung

Legal Events

Date Code Title Description
FA Abandonment or withdrawal